Who are LENSAR, Inc.'s main suppliers?

LENSAR, Inc. (LNSR) key suppliers include: WELLS-FARGO-BANK-N-A, SUPPLIERS, CHINA, GERMANY, SOUTH-KOREA and 4 more. View the full supplier network at chainsifter.com/chain/LNSR.

Who are LENSAR, Inc.'s major customers?

LENSAR, Inc. (LNSR) key customers include: ASCS, HOSPITALS, PHYSICIANS, PDL-BIOPHARMA-INC, Bausch Health Companies Inc. and 13 more. View the full customer network at chainsifter.com/chain/LNSR.

What sector is LENSAR, Inc. in?

LENSAR, Inc. (LNSR) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

LENSAR, Inc. Supplier List (LNSR): 9 Verified Suppliers

9Suppliers

18Customers

2Debt Items

20Related Chains

Source-Backed Evidence Depth

LENSAR, Inc. (LNSR) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

30Total relationships

4Distinct source URLs

12High confidence

0.753Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

LENSAR, Inc. Suppliers

Ticker	Name	Confidence	Evidence
WELLS-FARGO-BANK-N-A	WELLS-FARGO-BANK-N-A	92%	The PCL Agreement provides for a revolving, non-purpose margin credit facility, secured by a first-priority lien on a designated brokerage account maintained at Wells Fargo
SUPPLIERS	SUPPLIERS	85%	We purchase custom and off-the-shelf components from a number of suppliers, including some single-source suppliers.
CHINA	CHINA	80%	we sell our products through distributor relationships
GERMANY	GERMANY	80%	we sell our products through distributor relationships
SOUTH-KOREA	SOUTH-KOREA	80%	we sell our products through distributor relationships
BHC	Bausch Health Companies Inc.	72%	zation efforts will provide us with significant opportunity for future growth as we continue to penetrate existing and new markets. Our ALLY System currently is cleared for marketing in the United St…
BHC	Bausch Health Companies Inc.	72%	Reciprocal relationship from BHC graph: Reciprocal relationship from LNSR graph: zation efforts will provide us with significant opportunity for future growth as we continue to penetrate existing and…
JNJ	Johnson & Johnson	72%	zation efforts will provide us with significant opportunity for future growth as we continue to penetrate existing and new markets. Our ALLY System currently is cleared for marketing in the United St…
JNJ	Johnson & Johnson	72%	Reciprocal relationship from JNJ graph: Reciprocal relationship from LNSR graph: zation efforts will provide us with significant opportunity for future growth as we continue to penetrate existing and…

LENSAR, Inc. Customers

Ticker	Name	Confidence	Evidence
ASCS	ASCS	90%	we and our distributors typically market and sell our systems to ASCs, hospitals and physicians
HOSPITALS	HOSPITALS	90%	we and our distributors typically market and sell our systems to ASCs, hospitals and physicians
PHYSICIANS	PHYSICIANS	90%	we and our distributors typically market and sell our systems to ASCs, hospitals and physicians
PDL-BIOPHARMA-INC	PDL-BIOPHARMA-INC	85%	185 Total 2,756 2,872 Less accumulated depreciation ( 2,385 ) ( 2,381 ) Construction in progress 293 188 Property and equipment, net $ 664 $ 679 Depreciation expense on property and equipment amounte…
BHC	Bausch Health Companies Inc.	72%	Reciprocal relationship from BHC graph: Reciprocal relationship from LNSR graph: zation efforts will provide us with significant opportunity for future growth as we continue to penetrate existing and…
BHC	Bausch Health Companies Inc.	72%	zation efforts will provide us with significant opportunity for future growth as we continue to penetrate existing and new markets. Our ALLY System currently is cleared for marketing in the United St…
BLCO	Bausch + Lomb Corporation	72%	antee that the Company will be able to meet customer demand for the ALLY System. In addition, pricing increases in component parts for our Systems resulting from inflationary pressures and other macr…
BLCO	Bausch + Lomb Corporation	72%	Reciprocal relationship from BLCO graph: Reciprocal relationship from LNSR graph: Reciprocal relationship from BLCO graph: Reciprocal relationship from LNSR graph: Reciprocal relationship from BLCO g…
JNJ	Johnson & Johnson	72%	Reciprocal relationship from JNJ graph: Reciprocal relationship from LNSR graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from LNSR graph: zation efforts will provide us with s…
JNJ	Johnson & Johnson	72%	zation efforts will provide us with significant opportunity for future growth as we continue to penetrate existing and new markets. Our ALLY System currently is cleared for marketing in the United St…
AI-TECHNOLOGIES	AI-TECHNOLOGIES	62%	ore quickly or effectively adopt AI capabilities, or that our use of AI or other emerging technologies increases regulatory, cybersecurity and other significant risks. There can be no assurance that …
ALCON-RESEARCH-LLC	ALCON-RESEARCH-LLC	62%	ng of these clearances or certifications, among other factors. Our future revenue and cash flows will depend on, among other factors, our installed base of Systems and the timing of and applicable cl…
ARTIFICIAL-INTELLIGENCE-TECHNOLOGIES	ARTIFICIAL-INTELLIGENCE-TECHNOLOGIES	62%	res are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. An inability to incorporate technologies or features that are important or …
CARL-ZEISS-AG	CARL-ZEISS-AG	62%	antee that the Company will be able to meet customer demand for the ALLY System. In addition, pricing increases in component parts for our Systems resulting from inflationary pressures and other macr…
MERGER-SUB-INC	MERGER-SUB-INC	62%	Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Alcon (“Merger Sub”) has caused, and may continue to cause, a material disruption to our business. We also announced that the…
NR-GRI-PARTNERS	NR-GRI-PARTNERS	62%	cluding common stock, preferred stock, warrants, and/or debt securities through private placement transactions or registered public offerings in the future. If we issue equity securities to raise add…
VMI-OPTION-MERGER-SUB-INC	VMI-OPTION-MERGER-SUB-INC	62%	ng of these clearances or certifications, among other factors. Our future revenue and cash flows will depend on, among other factors, our installed base of Systems and the timing of and applicable cl…
ZEIMER-OPHTHALMIC-SYSTEMS-AG	ZEIMER-OPHTHALMIC-SYSTEMS-AG	62%	egulatory requirements of the FDA (and other regulatory authorities). In particular, the FDA’s Quality Management System Regulation, or QMSR, which includes FDA’s current Good Manufacturing Practice …

LENSAR, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
LNSR-DEBT-10744	Warrants outstanding: 10338000	90%	xbrl warrant detail from xbrl 2025-12-31.
LNSR-DEBT	Debt stack $2.6M	90%	Market cache reports total debt of $2.6M.

LENSAR, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for LENSAR, Inc..

LENSAR, Inc. Ownership

Holder	Name	Confidence	Evidence
LNSR-OWNER-BRANDES-INVESTMENT-PARTNERS-LP	BRANDES INVESTMENT PARTNERS, LP	90%	13F overlay lists BRANDES INVESTMENT PARTNERS, LP as top holder; 88 tracked holders.

LENSAR, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
BCAX	Bicara Therapeutics Inc.	100.00	2
AURA	Aura Biosciences, Inc.	100.00	2
ATRA	Atara Biotherapeutics, Inc.	100.00	2
BLCO	Bausch + Lomb Corporation	100.00	1	['customer']
ABBV	AbbVie Inc.	100.00	2
ACIU	AC Immune SA	100.00	2
AVBP	ArriVent BioPharma, Inc.	100.00	2
ANIK	Anika Therapeutics, Inc.	100.00	2
CLGN	CollPlant Biotechnologies Ltd.	100.00	2
BNR	Burning Rock Biotech Limited	100.00	2
BNRG	Brenmiller Energy Ltd	100.00	2
ADGM	Adagio Medical Holdings, Inc.	100.00	2
CSTE	Caesarstone Ltd.	100.00	2
AORT	Artivion, Inc.	100.00	2
SNNUF	Smith & Nephew plc	100.00	2
ALC	Alcon Inc.	100.00	2
CYTOF	Altamira Therapeutics Ltd.	100.00	2
BHC	Bausch Health Companies Inc.	100.00	1	['customer', 'supplier']
BLLN	BillionToOne, Inc.	100.00	2
ATON	AlphaTON Capital Corp	100.00	2

LENSAR, Inc. Supply Chain